Significant correlation of peptidyl-prolyl isomerase overexpression in merkel cell carcinoma with overall survival of patients

Head and Neck

Volumn 33, Issue 9, 2011, Pages 1294-1300

  Lill, Claudia ^a   Schneider, Sven ^a   Pammer, Johannes ^a   Loewe, Robert ^b   Gedlicka, Wilhelm ^a   Houben, Roland ^c   Heiduschka, Gregor ^a   Brunner, Markus ^a   Thurnher, Dietmar ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Universitatsklinik fur Dermatologie   (Austria)

^c UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Merkel cell carcinoma; PIN1; prognostic factor

Indexed keywords

PEPTIDYLPROLYL ISOMERASE PIN1;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MERKEL CELL TUMOR; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; WESTERN BLOTTING;

AGED; AGED, 80 AND OVER; CARCINOMA, MERKEL CELL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PEPTIDYLPROLYL ISOMERASE; PROGNOSIS; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; SURVIVAL ANALYSIS;

EID: 80051721184     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21596     Document Type: Article

References (27)

1. Lassacher A, Heitzer E, Kerl H, et al. P14ARF hypermetylation is common but INK4a-ARF locus or p53 mutations are rare in merkel cell carcinoma. J Invest Dermatol 2008; 128: 1788-1796. (Pubitemid 351847382)
2. Becker JC, Schrama D, Houben R,. Merkel Cell Carcinoma. Cell Mol Life Sci 2008; 66: 1-8.
3. Girschik J, Fritschi L, Threlfall T, et al. Deaths from non-melanoma skin cancer in Western Australia. Cancer Causes Control 2008; 19: 879-885.
4. Weller K, Vetter-Kauzcok C, Kähler K, et al. Guideline implementation in merkel cell carcinoma: an example of a rare disease. Dtsch Aerztebl 2008; 103: 2791-2796.
5. Woo K, Choi Y, Jung HS, et al. Merkel cell carcinoma: our experience with seven patients in Korea and a literature review. J Plast Reconstr Aesthet Surg 2010 Mar 4. [Epub ahead of print].
6. Zampetti A, Feliciani C, Massi G, Tulli A,. Updated review of the pathogenesis and management of merkel cell carcinoma. J Cutan Med Surg 2010; 14: 51-61.
7. Fukuchi M, Fukai Y, Kimura H, et al. Prolyl isomerase PIN1 expression predicts prognosis in patients with esophageal squamous cell carcinoma and correlates with cyclin D1 expression. Int J Oncol 2006; 29: 329-334.
8. Wulf G, Liou Y, Ryo A, et al. Role of PIN1 in the regulation of p53 stability and p21 transactivation, and cell cycle checkpoints in response to DNA damage. J Biol Chem 2002; 277: 47976-47979. (Pubitemid 35470742)
9. Patridge M, Costea DE, Huang X,. The changing face of p53 in head and neck cancer. Int J Oral Maxillofac Surg 2007; 36: 1123-1138. (Pubitemid 350138394)
10. Caldwell C, Zambetti G,. The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth. Gene 2001; 277: 15-30. (Pubitemid 32972107)
11. Lam PB, Burga LN, Wu BP, et al. Prolyl isomerase PIN1 is highly expressed in Her2-positive breast cancer and regulates erbB2 protein stabiliy. Mol Cancer 2008; 7: 91-103.
12. Leung KW, Tsai CH, Hsaio M, et al. Pin1 overexpression is associated with poor differentiation and survival in oral squamous cell carcinoma. Oncol Rep 2009; 21: 1097-1104.
13. Miyashita H, Uchida T, Mori S, et al. PIN1 is overexpressed in oral squamous cell carcinoma and its levels correlate with cyclin D1 overexpression. Oncol Rep 2003; 10: 455-461.
14. Ayala G, Wang D, Wulf G, et al. The prolyl isomerase Pin1 is a novel prognostic marker in human prostate cancer. Cancer Res 2003; 63: 6244-6251. (Pubitemid 37255170)
15. Yiengpruksawan A, Coit DG, Thaler HT, et al. Merkel cell carcinoma. Prognosis and management. Arch Surg 1991; 126: 1514-1519.
16. Sur M, AlArdati H, Ross C, et al. TdT expression in Merkel cell carcinoma: potential diagnostic pitfall with blastic hematological malignancies and expanded immunohistochemical analysis. Mod Pathol 2007; 20: 1113-1120. (Pubitemid 47609060)
17. Brunner M, Thurnher D, Pammer J, et al. Expression of hedgehog signaling molecules in Merkel cell carcinoma. Head Neck 2009; 32: 333-340.
18. Skelton HG, Smith KJ, Hitchcock CL, et al. Merkel cell carcinoma: analysis of clinical, histologic, and immunohistologic features of 132 cases with relation to survival. J Am Acad Dermatol 1997; 37: 734-739. (Pubitemid 27500317)
19. Agar NS, Halliday GM, Barnetson RS, et al. The basal layer in human squamous tumors harbors more UVA than UVB fingerprint mutations: a role for UVA in human skin carcinogenesis. Proc Natl Acad Sci USA 2004; 101: 4954-4959 (Pubitemid 38469184)
20. Melnikova VO, Pacifico A, Chimenti S, et al. Fate of UVB-induced p53 mutations in SKH-hr1 mouse skin after discontinuation of irradiation: relationship to skin cancer development. Oncogene 2005; 24: 7055-7063. (Pubitemid 41573634)
21. Giglia-Mari G, Sarasin A,. TP53 mutations in human skin cancers. Hum Mutat 2003; 21: 217-228. (Pubitemid 36292964)
22. Ramqvist T, Dalianis T,. Lessons from immune responses and vaccines against murine polyomavirus infection and polyomavirus-induced tumours potentially useful for studies on human polyomaviruses. Anticancer Res 2010; 30: 279-284.
23. Nakamura T, Sato Y, Watanabe D, et al. Nuclear localization of Merkel cell polyomavirus large T antigen in Merkel cell carcinoma. Virology 2010; 398: 273-279.
24. Duncavage EJ, Le BM, Wang D, et al. Merkel cell polyomavirus: a specific marker for Merkel cell carcinoma in histologically similar tumors. Am J Surg Pathol 2009; 33: 1771-1777.
25. Bhatia K, Goedert J, Modali R, et al. Merkel cell carcinoma subgroups by Merkel cell polyomavirus DNA relative abundance and oncogene expression. Int J Cancer 2009; 126: 2240-2246.
26. Acebo E, Vidaurrazaga N, Varas C, et al. Merkel cell carcinoma: a clinicophathological study of 11 cases. J Eur Acad Dermatol Venerol 2005; 19: 546-551. (Pubitemid 41742833)
27. Lu J, Hu Z, Wei S, et al. A novel function variant (-842G>C) in the PIN1 promoter contributes to decreased risk of squamous cell carcinoma of the head and neck by diminishing the promoter activity. Carcinogenesis 2009; 30: 1717-1721.